FDG PET-MRI for the Diagnosis of Spinal Cord Lesions

• Status: Completed
• Trial end date: 2024-05-07
• Target enrollment: 0
• Participant gender: All

Summary

To compare the results and understand the possible benefits from FDG-PET/MRI during different scanning time points after FDG, a type of contrast drug, is given.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Collaborator: National Cancer Institute (NCI)
• Treatments: Deoxyglucose; Fluorodeoxyglucose F18

Criteria

Inclusion Criteria:

• Patients with untreated intramedullary cord lesion(s)

• Ability to undergo FDG PET MR examination

Exclusion Criteria:

• No prior surgery or biopsy of the spinal cord

• No metal implanted in area of interest

• Spine radiation therapy

• Known allergy to FDG or gadolinium based contrast agents

• Blood glucose (> 200 mg/dl)

• Pregnant women are excluded

• Children of less than 18 years of age

• Need for conscious sedation or anesthesia in order to tolerate study